Loading…
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $58M | $-20M | $-34M | $-15M | 131.7% | 9.2% | - |
| 2024 | $53M | $-3M | $-31M | $-2M | -645.9% | 26.9% | - |
| 2023 | $42M | $-9M | $-14M | $-10M | -43.0% | 19.2% | - |
| 2022 | $35M | $-17M | $-20M | $-15M | -47.4% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 35.36 | 42.16 | 53.49 | 58.44 |
| Cost Of Revenue | 15.40 | 21.06 | 27.64 | 31.31 |
| Gross Profit | 19.95 | 21.11 | 25.85 | 27.12 |
| Operating Expense | 40.13 | 33.34 | 32.79 | 51.70 |
| Operating Income | -20.18 | -12.23 | -6.94 | -24.58 |
| EBITDA | -16.77 | -8.71 | -3 | -20.08 |
| EBIT | -20.18 | -12.23 | -6.94 | -24.58 |
| Pretax Income | -19.91 | -14.38 | -31.40 | -34.28 |
| Net Income | -19.91 | -14.38 | -31.40 | -34.28 |
| Net Income Common Stockholders | -19.91 | -14.38 | -31.40 | -34.28 |
| Total Expenses | 55.53 | 54.39 | 60.43 | 83.01 |
| Interest Expense | 0 | 0 | 0 | 0 |
| Research And Development | 11.81 | 6.14 | 5.33 | 5.62 |
| Selling General And Administration | 27.17 | 26.10 | 26.49 | 45.16 |
| Normalized EBITDA | -16.77 | -5.86 | 22.12 | -9.74 |
| Normalized Income | -19.91 | -11.53 | -6.28 | -23.94 |
| Basic EPS | -1.96 | -1.31 | -2.73 | -2.87 |
| Diluted EPS | -1.96 | -1.31 | -2.73 | -2.87 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0 | -2.85 | -25.13 | -10.34 |
| Total Unusual Items Excluding Goodwill | 0 | -2.85 | -25.13 | -10.34 |
| Net Income From Continuing Operation Net Minority Interest | -19.91 | -14.38 | -31.40 | -34.28 |
| Reconciled Depreciation | 3.41 | 3.52 | 3.93 | 4.50 |
| Reconciled Cost Of Revenue | 13.14 | 18.64 | 24.68 | 27.73 |
| Net Interest Income | 0 | 0 | 0 | 0 |
| Net Income From Continuing And Discontinued Operation | -19.91 | -14.38 | -31.40 | -34.28 |
| Total Operating Income As Reported | -20.18 | -12.23 | -10.66 | -24.58 |
| Diluted Average Shares | 10.16 | 10.97 | 11.52 | 11.96 |
| Basic Average Shares | 10.16 | 10.97 | 11.52 | 11.96 |
| Diluted NI Availto Com Stockholders | -19.91 | -14.38 | -31.40 | -34.28 |
| Net Income Including Noncontrolling Interests | -19.91 | -14.38 | -31.40 | -34.28 |
| Net Income Continuous Operations | -19.91 | -14.38 | -31.40 | -34.28 |
| Other Income Expense | 0.26 | -2.15 | -24.47 | -9.70 |
| Other Non Operating Income Expenses | 0.26 | 0.70 | 0.66 | 0.64 |
| Special Income Charges | 0 | 0 | -3.73 | 0 |
| Impairment Of Capital Assets | 0 | 0 | 3.73 | 0 |
| Gain On Sale Of Security | 0 | -2.85 | -21.40 | -10.34 |
| Net Non Operating Interest Income Expense | 0 | 0 | 0 | 0 |
| Interest Expense Non Operating | 0 | 0 | 0 | 0 |
| Depreciation Amortization Depletion Income Statement | 1.15 | 1.10 | 0.97 | 0.92 |
| Depreciation And Amortization In Income Statement | 1.15 | 1.10 | 0.97 | 0.92 |
| Amortization | 1.15 | 1.10 | 0.97 | 0.92 |
| Amortization Of Intangibles Income Statement | 1.15 | 1.10 | 0.97 | 0.92 |
| Operating Revenue | 35.36 | 42.16 | 53.49 | 58.44 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| LENSAR, Inc.this co. | LNSR | $65M | - | -2.48 | 131.7% | -3.17 |
| biote Corp. | BTMD | $83M | 3.00 | -1.16 | -53.7% | 4.32 |
| Gossamer Bio, Inc. | GOSS | $82M | - | -0.67 | 138.8% | -0.91 |
| Outset Medical, Inc. | OM | $77M | - | 0.60 | -64.3% | -0.14 |
| aTyr Pharma, Inc. | ATYR | $75M | - | 1.11 | -110.2% |
| -0.11 |
| DocGo Inc. | DCGO | $70M | - | 0.48 | -144.9% | -0.41 |
| Actuate Therapeutics, Inc. Common stock | ACTU | $68M | - | 8.45 | -280.5% | - |
| Pulmonx Corporation | LUNG | $51M | - | 0.92 | -99.8% | -0.71 |
| Accuray Incorporated | ARAY | $50M | - | 0.94 | -2.0% | -107.66 |
| Peer Median | - | 3.00 | 0.76 | -82.1% | -0.41 | |